Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
$1.08
+0.9%
$1.14
$0.60
$4.18
$48.01M0.62438,779 shs544,877 shs
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
$1.12
+0.9%
$0.99
$0.65
$1.75
$66.22M-0.02519,062 shs255,989 shs
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
$18.92
+12.3%
$15.72
$2.70
$38.25
$48.99M0.67912,550 shs248,957 shs
Synlogic, Inc. stock logo
SYBX
Synlogic
$1.22
-1.5%
$1.18
$0.90
$1.88
$14.50M0.5516,917 shs3,054 shs
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
+0.93%-0.09%-18.80%+52.11%-50.91%
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
+0.90%+12.00%+9.80%+58.08%+111,999,900.00%
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
+12.28%+10.32%+30.03%+172.62%+1,891,999,900.00%
Synlogic, Inc. stock logo
SYBX
Synlogic
-1.53%+2.09%-4.24%+20.30%-16.94%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
3.1056 of 5 stars
3.53.00.00.00.05.00.6
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
1.5612 of 5 stars
3.50.00.00.01.20.00.6
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
N/AN/AN/AN/AN/AN/AN/AN/A
Synlogic, Inc. stock logo
SYBX
Synlogic
0.4236 of 5 stars
0.03.00.00.00.01.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
3.00
Buy$8.33671.60% Upside
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
3.00
Buy$7.33554.76% Upside
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
0.00
N/AN/AN/A
Synlogic, Inc. stock logo
SYBX
Synlogic
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest SYBX, HOWL, QNTM, and IRD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/27/2025
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00
6/18/2025
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
Singular Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeModerate Buy
5/9/2025
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$8.00 ➝ $6.00
4/11/2025
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$6.00
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
$1.88M25.78N/AN/A$1.65 per share0.65
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
$10.99M6.08N/AN/A$0.21 per share5.33
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
N/AN/AN/AN/A$4.54 per shareN/A
Synlogic, Inc. stock logo
SYBX
Synlogic
$10K1,428.57N/AN/A$1.09 per share1.12
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
-$70.51M-$1.67N/AN/AN/AN/A-89.37%-54.87%8/14/2025 (Estimated)
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
-$57.53M-$2.10N/AN/AN/A-429.42%-283.28%-144.32%8/12/2025 (Estimated)
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
-$14.20M-$15.98N/AN/AN/AN/A-155.20%-94.90%8/13/2025 (Estimated)
Synlogic, Inc. stock logo
SYBX
Synlogic
-$23.36M-$2.51N/AN/AN/AN/A10.91%7.47%8/6/2025 (Estimated)

Latest SYBX, HOWL, QNTM, and IRD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
-$0.34-$0.32+$0.02-$0.24$4.00 million$4.30 million
5/14/2025Q1 2025
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
-$0.37-$1.41-$1.04-$3.53$2.09 million$2.09 million
5/8/2025Q1 2025
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
-$0.44-$0.40+$0.04-$0.40$0.30 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
N/AN/AN/AN/AN/A
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
N/AN/AN/AN/AN/A
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
N/AN/AN/AN/AN/A
Synlogic, Inc. stock logo
SYBX
Synlogic
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
0.46
8.09
8.09
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
N/A
1.98
1.98
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
N/A
0.96
0.95
Synlogic, Inc. stock logo
SYBX
Synlogic
N/A
3.68
3.68

Institutional Ownership

CompanyInstitutional Ownership
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
64.84%
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
14.97%
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
1.24%
Synlogic, Inc. stock logo
SYBX
Synlogic
63.40%

Insider Ownership

CompanyInsider Ownership
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
23.60%
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
6.60%
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
8.53%
Synlogic, Inc. stock logo
SYBX
Synlogic
3.02%
CompanyEmployeesShares OutstandingFree FloatOptionable
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
4044.87 million34.28 millionOptionable
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
1459.66 million55.72 millionN/A
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
N/A2.91 million2.66 millionN/A
Synlogic, Inc. stock logo
SYBX
Synlogic
8011.70 million11.34 millionOptionable

Recent News About These Companies

Synlogic Reports Q3 2024 Financial Outcomes
Synlogic Reports Third Quarter 2024 Financial Results
Synlogic, Inc. (0A8U.L)
MIN.SG,0P0001I7V6,0 (MIN.SG)
SYBX Stock Earnings: Synlogic Beats EPS for Q2 2024
Synlogic Reports Second Quarter 2024 Financial Results
Synlogic Inc.
Synlogic Inc SYBX
Synlogic Flat on Q1 Numbers
Synlogic Reports First Quarter 2024 Financial Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

Werewolf Therapeutics stock logo

Werewolf Therapeutics NASDAQ:HOWL

$1.08 +0.01 (+0.93%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$1.09 +0.01 (+0.93%)
As of 07/10/2025 06:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

Opus Genetics stock logo

Opus Genetics NASDAQ:IRD

$1.12 +0.01 (+0.90%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$1.14 +0.01 (+1.34%)
As of 07/10/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.

Quantum Biopharma stock logo

Quantum Biopharma NASDAQ:QNTM

$18.92 +2.07 (+12.28%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$18.92 +0.00 (+0.03%)
As of 07/10/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

Synlogic stock logo

Synlogic NASDAQ:SYBX

$1.22 -0.02 (-1.53%)
Closing price 07/10/2025 03:57 PM Eastern
Extended Trading
$1.22 +0.00 (+0.25%)
As of 07/10/2025 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.